FDA panel votes against J&J cancer drug benefits

Courtesy Newsvine - business  Wed, 07/15/2009 - 10:28

A Food and Drug Administration panel has ruled that the benefits of an experimental drug from Johnson & Johnson do not outweigh its risks, according to an agency spokeswoman.


 

Related items

FDA panel wants more data on Genzyme cancer drug
A panel of cancer experts has issued a negative review of a leukemia drug from Genzyme, saying more data is needed to establish its safety and efficacy for older patients.

FDA questions data for J&J ovarian cancer drug
Food and Drug Administration scientists are questioning whether study results are reliable enough to warrant approval for a new cancer drug from Johnson & Johnson.

FDA rejects GlaxoSmithKline nausea, vomiting drug
The U.S. Food and Drug Administration has rejected GlaxoSmithKline PLC's application to approve an experimental drug for nausea and vomiting.

BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
The X5 Stereo Bluetooth Headset is a portable multi-function device utilizing the latest cutting edge technologies allowing you to stream high quality music and make voice calls using a...

Uniden TRU9496 2-Line Corded/Cordless Digital...
With the Uniden TRU9496 5.8 GHz Digital 2-Line Expandable Phone System is the next generation of 5.8 GHz cordless phones. It's a full-featured digital answerer, with a Dialing keypad and a...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
We apologize for the inconvenience. Please help fight spam.
business.marc8.com